Reynders McVeigh Capital Management LLC Has $7.15 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Reynders McVeigh Capital Management LLC trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 36.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,340 shares of the life sciences company's stock after selling 29,366 shares during the quarter. Reynders McVeigh Capital Management LLC's holdings in Illumina were worth $7,149,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Illumina in the 3rd quarter valued at about $30,000. VisionPoint Advisory Group LLC raised its holdings in shares of Illumina by 344.6% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company's stock valued at $34,000 after purchasing an additional 193 shares in the last quarter. Wetzel Investment Advisors Inc. purchased a new stake in shares of Illumina during the 4th quarter worth $37,000. Gradient Investments LLC grew its stake in shares of Illumina by 375.0% during the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company's stock worth $40,000 after purchasing an additional 225 shares in the last quarter. Finally, North Star Investment Management Corp. raised its stake in Illumina by 183.0% in the fourth quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company's stock valued at $42,000 after buying an additional 194 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently commented on ILMN. Barclays increased their price objective on Illumina from $85.00 to $100.00 and gave the company an "underweight" rating in a report on Wednesday, April 10th. Robert W. Baird boosted their price objective on shares of Illumina from $125.00 to $128.00 and gave the stock a "neutral" rating in a research report on Friday, May 3rd. Scotiabank dropped their target price on shares of Illumina from $185.00 to $176.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 6th. HSBC lowered shares of Illumina from a "buy" rating to a "hold" rating in a research note on Tuesday, January 16th. Finally, StockNews.com upgraded shares of Illumina from a "hold" rating to a "buy" rating in a research note on Saturday. Two analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $164.65.

Illumina Stock Performance

Illumina stock traded down $0.82 during trading hours on Friday, reaching $110.53. 1,179,720 shares of the stock were exchanged, compared to its average volume of 1,648,134. The stock has a market cap of $17.61 billion, a P/E ratio of -13.56 and a beta of 1.20. The firm's 50 day moving average is $127.36 and its 200 day moving average is $126.66. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.75. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $213.91.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The business had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.05 billion. During the same period last year, the firm earned $0.08 EPS. The company's quarterly revenue was down 1.0% compared to the same quarter last year. Analysts predict that Illumina, Inc. will post 0.87 EPS for the current fiscal year.

Insider Transactions at Illumina

In related news, CEO Jacob Thaysen acquired 7,330 shares of Illumina stock in a transaction that occurred on Thursday, February 22nd. The stock was purchased at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the purchase, the chief executive officer now directly owns 14,861 shares of the company's stock, valued at $2,010,544.69. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.17% of the company's stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.